Morgan Stanley upgrades AstraZeneca to Overweight

A Morgan Stanley analyst upgraded AstraZeneca (LON: AZN) from Equalweight to Overweight with a price target of $132.00 from a prior price target of %currency%%price%.
Prior to this rating, AstraZeneca had 23 buy ratings, 7 hold ratings, and 0 sell ratings.
For consensus analyst estimates and price targets on AstraZeneca, click here. For more news on AstraZeneca, click here.
AstraZeneca's stock price closed at $11.0. They are up -99.9% in the last month and up 11.2% in the last 12 months.
According to Investing Pro, AstraZeneca's fair value is $130.2, an upside of 11.2%. AstraZeneca's fair value comes with a low degree of uncertainty, according to InvestingPro.
Check out AstraZeneca's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or